Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Mądry K, Lis K, Fenaux P, Bowen D, Symeonidis A, Mittelman M, Stauder R, Čermák J, Sanz G, Hellström-Lindberg E, Langemeijer S, Malcovati L, Germing U, Holm MS, Guerci-Bresler A, Culligan D, Sanhes L, Kotsianidis I, van Marrewijk C, Crouch S, de Witte T, Smith A; EUMDS Registry Participants. Mądry K, et al. Among authors: culligan d. Br J Haematol. 2023 Feb;200(4):451-461. doi: 10.1111/bjh.18542. Epub 2022 Nov 6. Br J Haematol. 2023. PMID: 36335984
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project.
Efficace F, Koinig K, Cottone F, Bowen D, Mittelman M, Sommer K, Langemeijer S, Culligan D, Filanovsky K, Storck M, Smith A, van Marrewijk C, Dugas M, Stojkov I, Siebert U, de Witte T, Stauder R. Efficace F, et al. Among authors: culligan d. Cancer Med. 2023 Mar;12(6):7529-7539. doi: 10.1002/cam4.5487. Epub 2022 Dec 19. Cancer Med. 2023. PMID: 36533415 Free PMC article.
Dek-can rearrangement in translocation (6;9)(p23;q34).
Soekarman D, von Lindern M, van der Plas DC, Selleri L, Bartram CR, Martiat P, Culligan D, Padua RA, Hasper-Voogt KP, Hagemeijer A, et al. Soekarman D, et al. Among authors: culligan d. Leukemia. 1992 Jun;6(6):489-94. Leukemia. 1992. PMID: 1602786
H RAS mutations in haematologically normal individuals.
Taylor C, Larghero J, Thomas C, Warren N, Carter G, Hughes D, Culligan D, Al-Sabah A, Whittaker JA, Chomienne C, Padua RA. Taylor C, et al. Among authors: culligan d. Hematol J. 2000;1(6):399-402. doi: 10.1038/sj.thj.6200060. Hematol J. 2000. PMID: 11920220
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.
Dennis M, Culligan D, Karamitros D, Vyas P, Johnson P, Russell NH, Cavenagh J, Szubert A, Hartley S, Brown J, Bowen D. Dennis M, et al. Among authors: culligan d. Leuk Res Rep. 2013 Aug 28;2(2):70-4. doi: 10.1016/j.lrr.2013.07.003. eCollection 2013. Leuk Res Rep. 2013. PMID: 24371786 Free PMC article.
101 results